GAU 1635

Please type a plus sign (+) inside this box -

Signature

PTO/SB/21(08-00)
Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of	f 1995, no persor	o.s. Patent and Tra	nformation unless it displays a valid OMB control number.
TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	09/417,251
		Filing Date	October 13, 1999
		First Named Inventor	R. Cahoon et al.
		Group Art Unit	1635
		Examiner Name	J. Zara
Total Number of Pages in This Submission		Attorney Docket Number	BB1085 US NA
ENCLOSURES (check all that apply)			
Fee Transmittal Form	Assignment Papers (for an Application)		After Allowance Communication to Group
Fee Attached	Drawing(s)		Appeal Communication to Board of Appeals and Interferences
Amendment / Response	Licensing-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
☐ After Final ☐ Affidavits/declaration(s)	Petition		Proprietary Information
Extension of Time Request	Petition to Convert to a Provisional Application		Status Letter
Express Abandonment Request	Power of Attorney, Revocation Change of Correspondence Address		Other Enclosure(s) (please identify below):
Information Disclosure Statement	Terminal Disclaimer		RECEIVED
Certified Copy of Priority Document(s)	Request for Refund		APR 1 8 2001
Response to Missing Parts/ Incomplete Application	CD, Number of CD(s)		TECH CENTER 1600/2900
Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Individual name KENING LI			
Signature			
Date APRIL 12, 2001			
CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope			
addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: APRIL 12, 2001			
Typed or printed name LISA Z. TURNER			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Date

APRIL 12, 2001

IN THE PROPERTY STATES PATENT AND TRADEMARK OFFICE

In the Application of:

R. E. CAHOON ET AL.

APPLICATION NO.: 09/417,251

APR 1 6 2001

FILED: OCTOBER 13, 1999

CASE NO.: BB1085-US-NA

GROUP ART UNIT: 1635

EXAMINER: J. ZARA

FOR: PLANT PROTEIN DISULFIDE ISOMERASES

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action mailed March 16, 2001, please amend the application as follows:

RECEIVED

In the specification:

Please replace the following paragraphs:

Paragraph starting at page 4, line 12:

APR 1 8 2001

TECH CENTER 1600/2900

It is preferred that the isolated polynucleotides of the claimed invention consist of a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, and 19 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18 and 20. The present invention also relates to an isolated polynucleotide comprising a nucleotide sequence of at least 40 (preferably at least 30, most preferably at least 15) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, and 19 and the complement of such nucleotide sequences.

Paragraph starting at page 5, line 11:

The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of a protein disulfide isomerase precursor or an RB60 polypeptide, preferably a plant protein disulfide isomerase precursor or an RB60 polypeptide, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least 40 (preferably at least 30, most preferably at least 15) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, and 19 and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the



